{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '17', 'BIBLIOGRAPHY', '1. Sweeney CJ, Chen YH, Carducci M, et al: Chemohormonal Therapy in Metastatic Hormone-', 'Sensitive Prostate Cancer. N Engl J Med 373:737-46, 2015', '2.', 'James ND, Sydes MR, Clarke NW, et al: Addition of docetaxel, zoledronic acid, or both to', 'first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from', 'an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163-77,', '2016', '3. Fizazi K, Tran N, Fein L, et al: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive', 'Prostate Cancer. N Engl J Med 377:352-360, 2017', '4.', 'James ND, de Bono JS, Spears MR, et al: Abiraterone for Prostate Cancer Not Previously', 'Treated with Hormone Therapy. N Engl J Med 377:338-351, 2017', '5. Morris MJ, Rumble RB, Basch E, et al: Optimizing Anticancer Therapy in Metastatic Non-', 'Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.', 'J Clin Oncol:JCO2018780619, 2018', '6. STAMPEDE: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer', '(STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis.', 'J Clin Oncol 36, (suppl 6S; abstr 162), 2018', '7.', 'Chi KN, Protheroe A, Rodriguez-Antolin A, et al: Patient-reported outcomes following', 'abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with', 'newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international,', 'randomised phase 3 trial. Lancet Oncol 19:194-206, 2018', '8. Morgans AK, Chen YH, Sweeney CJ, et al: Quality of Life During Treatment With', 'Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation', 'Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095, 2018', '9. Antonarakis ES, Lu C, Luber B, et al: Clinical Significance of Androgen Receptor Splice', 'Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-', 'Resistant Prostate Cancer Treated With First-a and Second-Line Abiraterone and Enzalutamide.', 'J Clin Oncol 35:2149-2156, 2017', '10. Antonarakis ES, Lu C, Luber B, et al: Androgen Receptor Splice Variant 7 and Efficacy of', 'Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.', 'JAMA Oncol 1:582-91, 2015', '11. Maughan BL, Guedes LB, Boucher K, et al: p53 status in the primary tumor predicts efficacy', 'of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate', 'Cancer Prostatic Dis, 2018', '12. Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after', 'androgen deprivation is a strong independent predictor of survival in new metastatic prostate', 'cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24:3984-', '90, 2006', '13. Harshman LC, Chen YH, Liu G, et al: Seven-Month Prostate-Specific Antigen Is Prognostic', 'in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With', 'or Without Docetaxel. J Clin Oncol 36:376-382, 2018', '14. Esper P, Mo F, Chodak G, et al: Measuring quality of life in men with prostate cancer using', 'the functional assessment of cancer therapy-prostate instrument. Urology 50:920-8, 1997', '15. Calhoun EA, Welshman EE, Chang CH, et al: Psychometric evaluation of the Functional', 'Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx)', 'Page 40 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741-8,', '2003', '16. Cook KF, Jensen SE, Schalet BD, et al: PROMIS measures of pain, fatigue, negative affect,', 'physical function, and social function demonstrated clinical validity across a range of chronic', 'conditions. J Clin Epidemiol 73:89-102, 2016', '17. Tunes da Silva G, Logan BR, Klein JP: Methods for equivalence and noninferiority testing.', 'Biol Blood Marrow Transplant 15:120-7, 2009', '18. Scher HI, Morris MJ, Stadler WM, et al: DOI: 10.1200/JCO.2015.64.2702 Journal of Clinical', 'Oncology 34, no. 12 (April 20 2016) 1402-1418.', 'Page 41 of 52']\n\n###\n\n", "completion": "END"}